BMC Pulmonary Medicine最新文献

{"title":"A novel disulfidptosis-related mRNA signature predicts prognosis and therapeutic response in lung squamous cell carcinoma.","authors":"Wei Bai, Ning Jiang, Yuhan Deng, Xiaofeng Tang, Feifei Zhang, Shaorui Niu, Yuyang Yao, Yuhao Zhou, Kangming Chen, Liping Li, Jun Yang, Xiao-Bin Lv","doi":"10.1186/s12890-025-03920-6","DOIUrl":"10.1186/s12890-025-03920-6","url":null,"abstract":"<p><strong>Background: </strong>Lung squamous cell carcinoma (LUSC) remains an aggressive malignancy with limited therapeutic options and poor prognosis. Recent studies have identified disulfidptosis as a novel form of metabolic stress-induced cell death, but its clinical implications in LUSC remain unexplored. This study investigates the prognostic value of disulfidptosis-related genes (DRGs) in LUSC.</p><p><strong>Methods: </strong>We analyzed transcriptomic data from TCGA-LUSC cohort and identified DRGs through intersection with established disulfidptosis-related gene sets. A protein-protein interaction (PPI) network was constructed, and univariate Cox regression was performed to select prognostic genes. A risk score model was developed using multivariate Cox regression. The model's performance was evaluated using ROC curve and Kaplan-Meier analyses. Functional enrichment and immune microenvironment analyses were conducted to explore potential mechanisms.</p><p><strong>Results: </strong>We identified 9 prognostic DRGs (FHOD1, ORC5, TRIR, ALKBH1, EPS8L2, MBLAC1, MYADM, HTRA2, and SRI) that significantly correlated with patient survival. The risk score model effectively stratified patients into high- and low-risk groups (P < 0.001), with C-index values of 0.78 at 1 year and 0.75 at 3 years. High-risk patients showed enriched cytokine-cytokine receptor interactions and immunosuppressive microenvironments, while low-risk patients exhibited activated metabolic pathways. Experimental validation confirmed ORC5's oncogenic role in promoting proliferation and invasion.</p><p><strong>Conclusion: </strong>We established a novel 9-gene prognostic signature based on disulfidptosis-related genes that effectively predicts LUSC outcomes. These findings highlight the clinical relevance of disulfidptosis in LUSC and provide potential biomarkers for risk stratification and therapeutic targeting.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"462"},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impulse oscillometry for the detection of small airway dysfunction in patients with chronic respiratory symptoms, preserved ratio impaired spirometry and COPD.","authors":"Xia Gong, Le Sang, Yunlei Huang, Hua Wang, Jian Sun","doi":"10.1186/s12890-025-03941-1","DOIUrl":"10.1186/s12890-025-03941-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Persistent chronic airway inflammation and progressive airflow limitation are typical features of chronic obstructive pulmonary disease (COPD). Emerging evidence indicates that small airway dysfunction (SAD) plays a critical role in driving the sustained pathological progression of COPD. Preserved ratio impaired spirometry (PRISm) represents a spirometric pattern characterized by a reduced forced expiratory volume in 1 second (FEV₁) despite a preserved ratio. Current evidence inadequately elucidates the pathophysiological role of SAD and its intricate interplay with PRISm and COPD progression. On the other hand, impulse oscillometry (IOS) can be used as a complementary tool to spirometry to detect SAD. Detection of SAD in patients with chronic respiratory symptoms could help in the diagnosis of PRISm and COPD when spirometry is not achievable.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the diagnostic value of IOS for identifying SAD in patients with chronic respiratory symptoms, PRISm and COPD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Between September 2021 and July 2023, 552 symptomatic patients without known structural lung disease who underwent both spirometry and IOS on the same day in the outpatient clinic were evaluated. The correlations between spirometry and the IOS parameters, and the ROC curves of the IOS parameters for SAD patients and COPD patients were analyzed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 552 patients included in the study, 96 patients had COPD, 39 patients had PRISm, and 417 patients had chronic cough. Among 456 chronic cough patients with preserved ratio spirometry, the incidence of PRISm was 8.55%. Based on spirometry-defined SAD, the incidence of SAD in the PRISm population was 71.8%, which was significantly higher than the 9.35% of the non-PRISm population. With increasing COPD GOLD stage, the IOS parameters R5-R20, R5, Fres, and Ax increased, whereas the traditional lung function parameters and X5 decreased. R5-R20, X5, Fres, and AX of COPD GOLD stage 1 patients were not substantially different from those of PRISm patients. In PRISm patients, R5-R20, R5 and Fres were strongly correlated with FEF&lt;sub&gt;25%-75%&lt;/sub&gt;. R5-R20, R5, X5, Fres and AX were significantly associated with FEV&lt;sub&gt;1&lt;/sub&gt;, FEV&lt;sub&gt;1&lt;/sub&gt;/FVC, FEV&lt;sub&gt;1&lt;/sub&gt;% predicted, FEF&lt;sub&gt;50%&lt;/sub&gt;, FEF&lt;sub&gt;75%&lt;/sub&gt; and FEF&lt;sub&gt;25%-75%&lt;/sub&gt; in COPD patients. Through ROC curve analysis, the cutoffs for identifying SAD in patients with chronic respiratory symptoms and PRISm patients were obtained, with R5-R20 values of 0.075 and 0.105 kPa/L/s, respectively. The values of R5 were 0.365 and 0.375 kPa/L/s, respectively. The Fres values are 16.31 Hz and 17.11 Hz, respectively. The cutoff for detecting COPD in all patients was 0.485 kPa/L/s for R5, 0.125 kPa/L/s for R5-R20, -0.155 kPa/L/s for X5, and 17.98 Hz for Fres. Fres had the highest AUC value for both SAD and COPD detection, and it detected COPD the most in all patients, w","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"458"},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blowing devices, resources and incentive screens during respiratory physiotherapy: a systematic review.","authors":"Thaise Helena Cadorin, Juliana Cardoso, Tayná Castilho, Gabriela Castilhos Ducati, Renata Maba Gonçalves Wamosy, Camila Isabel Santos Schivinski","doi":"10.1186/s12890-025-03801-y","DOIUrl":"10.1186/s12890-025-03801-y","url":null,"abstract":"","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"459"},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of adherence to inhaler use in patients with asthma: the role of knowledge, self-efficacy, and perceived barriers.","authors":"Saeed Hosseininia, Sousan Mohammadikebar, Leila Motashakkeri, Aziz Kamran","doi":"10.1186/s12890-025-03919-z","DOIUrl":"10.1186/s12890-025-03919-z","url":null,"abstract":"<p><strong>Background: </strong>Adherence to inhaler therapy is a crucial determinant in the management and control of asthma. However, real-world evidence indicates that only 30-70% of patients adhere to prescribed treatments. This study aimed to identify the psychological and behavioral factors influencing inhaler adherence among patients with asthma.</p><p><strong>Methods: </strong>This cross-sectional study was conducted on 300 patients with a confirmed diagnosis of asthma based on GINA criteria at Imam Khomeini Hospital, Ardabil, Iran, during the winter of 2021-2022. Participants were selected through a census sampling method. Data were collected using a researcher-developed questionnaire and analyzed statistically.</p><p><strong>Results: </strong>Inhaler adherence was positively associated with patient knowledge, disease acceptance, treatment acceptance, self-efficacy, and perceived benefits of inhaler use. Conversely, fear of side effects and inhaler-related stigma were negatively associated with adherence (P < 0.05). Significant differences in adherence-related variables (knowledge, disease and treatment acceptance, stigma, self-efficacy, and perceived benefits) were found across different educational levels and between urban and rural patients (P < 0.05).</p><p><strong>Conclusions: </strong>Psychological and behavioral factors play a significant role in adherence to inhaler therapy in asthma patients. Regular assessment of patients' knowledge, beliefs, and behavioral patterns regarding inhaler use during clinical visits may enhance self-management and improve treatment outcomes.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"456"},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study.","authors":"Francesca Lalla, Angelo Latella, Francesco Varone, Bruno Iovene, Luca Richeldi, Giacomo Sgalla","doi":"10.1186/s12890-025-03916-2","DOIUrl":"10.1186/s12890-025-03916-2","url":null,"abstract":"<p><strong>Rationale: </strong>Limited data exists on the long-term comparative efficacy and tolerability of pirfenidone and nintedanib, the two approved treatments for idiopathic pulmonary fibrosis (IPF).</p><p><strong>Methods: </strong>We retrospectively enrolled IPF patients treated with either pirfenidone or nintedanib at our centre between 2017 and 2023. Progression-free survival (PFS), defined as time to death or ≥ 10% decline in % predicted forced vital capacity (FVC) and continuous FVC decline were compared between groups defined by antifibrotic type or treatment intensity (full or reduced). Time to drug dose reduction was also compared. Statistical analysis included Kaplan-Meier curves with Log-Rank tests, Cox proportional hazards models and linear mixed-effects models.</p><p><strong>Results: </strong>A total of 292 IPF patients treated with pirfenidone (n = 142) or nintedanib (n = 150) were included with a mean follow-up time of 32.3 months (SD = 14.5). No significant differences in efficacy were observed between groups by antifibrotic type. Dose reduction was more frequent in the nintedanib group (59.3%) than pirfenidone group (16.9%, p < 0.001). Multivariate analysis showed that patients on nintedanib had a 4-fold higher risk of dose reduction compared to those on pirfenidone (p < 0.001). There were no significant differences in clinical outcomes between patients with dose reduction and those maintaining the full dose, both in the overall population and when stratified by antifibrotic type.</p><p><strong>Conclusion: </strong>Nintedanib and pirfenidone exhibited similar long-term efficacy. Dose adjustment was more frequent with nintedanib, however it did not have impact on clinical outcomes.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"455"},"PeriodicalIF":2.8,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is 'better' enough? Prevalence and multidimensional portrait of persistent dyspnea upon discharge from a respiratory medicine ward: a prospective, single-center observational study.","authors":"Capucine Morélot-Panzini, Safaa Nemlaghi, Morgane Faure, Laure Serresse, Thomas Similowski","doi":"10.1186/s12890-025-03923-3","DOIUrl":"10.1186/s12890-025-03923-3","url":null,"abstract":"<p><strong>Background: </strong>During unplanned respiratory-related hospitalizations, gradual improvement in physiological variables and reduced dependence on treatment are crucial for discharge decisions, possibly supported by discharge care bundles designed to reduce post-hospitalization readmission and mortality. However, patients prioritize symptom relief. This study tested the hypothesis that a significant proportion of patients admitted to a pulmonology ward for an acute respiratory episode experience dyspnea on the day of discharge. It further aimed to describe this dyspnea in a multidimensional manner.</p><p><strong>Methods: </strong>This 10-week prospective study was conducted at a single center and included patients admitted for acute respiratory conditions such as COPD or asthma exacerbation, pneumonia, pulmonary embolism, or pleural disease, who, on admission, reported a rating of 3 or higher on the \"immediate breathing discomfort\" item of the Multidimensional Dyspnea Profile (MDP-A1). Dyspnea was assessed both at admission and at discharge using a multidimensional recall-based tool (MDP) and an instant unidimensional tool, the 10-cm visual analog scale (D-VAS).</p><p><strong>Results: </strong>Seventy consecutive patients were included in the study. Although dyspnea ratings showed a statistically significant decrease during the hospital stay, dyspnea remained both frequent and intense at discharge. At discharge, 84% of patients provided MDP-A1 recall ratings above 0, with 70% rating their MDP-A1 at 3 or more. In contrast, only 22% provided D-VAS instant ratings of 3 or higher. The median MDP-A1 score was 4.0 [2.0-6.0]. \"Air hunger\" was the most frequently selected sensory descriptor.</p><p><strong>Conclusions: </strong>Persistent dyspnea remains frequent and intense among patients being discharged after an acute respiratory episode.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"452"},"PeriodicalIF":2.8,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors and outcomes of ventilator-associated pneumonia: an updated systematic review and meta-analysis.","authors":"Paula Ochoa, Alejandro Rico Mendoza, Daniel Molano, Joan Ramon Masclans, Henry Mauricio Parada-Gereda","doi":"10.1186/s12890-025-03932-2","DOIUrl":"10.1186/s12890-025-03932-2","url":null,"abstract":"","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"453"},"PeriodicalIF":2.8,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning-based prediction of N2 lymph node metastasis in non-small cell lung cancer.","authors":"Eren Erdogdu, İlkay Öksüz, Salih Duman, Berker Ozkan, Sukru Mehmet Erturk, Doğu Vurallı Bakkaloğlu, Murat Kara, Alper Toker","doi":"10.1186/s12890-025-03921-5","DOIUrl":"10.1186/s12890-025-03921-5","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is a leading cause of cancer-related mortality worldwide. Accurate staging of mediastinal lymph nodes is a crucial step in determining appropriate treatment approaches. Current noninvasive diagnostic methods do not provide sufficient accuracy to confidently decide on surgery without histological confirmation. Our study aimed to develop a artificial intelligence model for the precise prediction of N2 lymph node metastasis.</p><p><strong>Methods: </strong>We retrospectively analyzed 1489 patients who underwent standard cervical mediastinoscopy at our department, including 472 patients diagnosed with non-small cell lung cancer. We developed three distinct prediction models for N2 lymph node station metastasis: one using standard statistical analysis, another utilizing an image processing deep learning algorithm with thoracic CT, and the third employing various machine learning methods with clinicopathological and radiological data. We compared diagnostic accuracy, area under the curve (AUC), sensitivity, and specificity rates, as well as the F1-score of all models.</p><p><strong>Results: </strong>Linear discriminant analysis, quadratic discriminant analysis, Gaussian naive Bayes, and artificial neural networks all surpassed 90% accuracy. The linear support vector machine demonstrated the highest performance, with an accuracy of 95.7%, an AUC of 93.5%, and an F1-score of 92%, respectively and outperformed the logistic regression-based statistical model, which reached an accuracy of 90.6% and an AUC of 85.7%.</p><p><strong>Conclusion: </strong>Machine learning models outperformed standard statistical analysis models in predicting N2 lymph node metastasis. Implementing these machine learning prediction models might greatly improve the accuracy of mediastinal lymph node metastasis detection, thereby enhancing clinical decision making and patient outcomes.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"454"},"PeriodicalIF":2.8,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal relationship between gut microbiota and pneumonia: a Mendelian randomization and retrospective case-control study.","authors":"Pengfei Huang, Yanqi Liu, Nana Li, Qianqian Zhang, Yinghao Luo, Yuxin Zhang, Yuxin Zhou, Wenjing Mu, Mengyao Yuan, Yuhan Liu, Yu Xin, Hongxu Li, Yahui Peng, Xibo Wang, Mingyan Zhao, Kaijiang Yu, Changsong Wang","doi":"10.1186/s12890-025-03899-0","DOIUrl":"10.1186/s12890-025-03899-0","url":null,"abstract":"<p><strong>Background: </strong>The relationship between microbiota and the gut-lung axis has been extensively studied in both experimental and epidemiological contexts. However, it is still unclear whether the gut microbiome plays a causal role in the development of pneumonia.</p><p><strong>Methods: </strong>Our study initially identified the genetic instruments in the gut microbiota GWAS across phylum, class, order, family, and genus levels. Pneumonia data were sourced from the open GWAS project of the Integrated Epidemiology Group (IEU). Mendelian randomization (MR) analysis employed several methods such as inverse variance weighting (IVW), weighted median, and MR-Egger, with Cochran's Q were calculated to assess heterogeneity via IVW and MR-Egger. Additionally, MR-PRESSO and MR-Egger intercepts were utilized to mitigate horizontal pleiotropy. A retrospective case-control study collected anal swab samples from severe pneumonia patients on the 1st and 3rd days after ICU admission. Samples were analyzed using 16S ribosomal ribonucleic acid (16S rRNA) and PERMANOVA analysis.</p><p><strong>Results: </strong>Eleven potential causal relationships between the gut microbiome and pneumonia (critical care), as well as nine potential causal relationships between the gut microbiome and pneumonia (28-day death in critical care) were identified. By integrating the results of PERMANOVA analysis with Mendelian randomization analysis, we were able to determine a negative correlation between genus Akkermansia and lactate levels, as well as length of ICU days in patients with septic acute respiratory distress syndrome (ARDS). Moreover, we found a potential negative causal relationship between the genus Akkermansia and pneumonia (28-day death in critical care) (OR 0.42, 95% CI 0.22-0.79, P = 0.007).</p><p><strong>Conclusions: </strong>Our Mendelian randomization analysis has provided evidence for a potential causal relationship between gut microbiota and pneumonia. Furthermore, we observed that the genus Akkermansia may decrease the risk of pneumonia (28-day death in critical care), as observed in septic ARDS patients which Akkermansia could reduce ICU days and lactate levels. These findings provide valuable insights into the gut-lung axis and have the latent to inform future research in this field.</p><p><strong>Trial registration: </strong>The study was registered at the Chinese Clinical Trial Registry ( https://www.chictr.org.cn/index.html , ChiCTR2300075450).</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"449"},"PeriodicalIF":2.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in tuberculosis-related mortality among adults 35-85 years old in the United States, 1999 to 2022: a nationwide analysis.","authors":"Olivia Foley, Natalie Perme, Taylor Billion, Abubakar Tauseef, Renuga Vivekenandan","doi":"10.1186/s12890-025-03931-3","DOIUrl":"10.1186/s12890-025-03931-3","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) is a significant cause of mortality in the United States (US), impairing individual health and causing national financial burden. Although TB-related mortality has declined in recent years, a variety of factors still make TB difficult to prevent, necessitating further analysis of which demographic groups are most impacted by TB.</p><p><strong>Methods: </strong>Trends in TB-related mortality in individuals aged 35 to 85 + years in the US from 1999 to 2022 were analyzed utilizing the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Following data collection, age-adjusted mortality rate (AAMR) and average annual percent change (AAPC) in TB-related mortality were examined. Data was further stratified by sex, race, age, region, and locality.</p><p><strong>Results: </strong>Between 1999 and 2022, there were 26,600 deaths related to TB in the US. Overall TB-related mortality significantly declined between 1999 and 2022 (AAPC, -3.95%). Males had consistently higher AAMR than females, with 16,741 deaths among males and 9,859 deaths among females. All racial groups, including Asian or Pacific Islander, Black or African American, White, and Hispanic or Latino individuals experienced significant declines in mortality (AAPC, -3.24%, -5.75%, -3.83%, -4.70%, respectively). Asian or Pacific Islander, Black or African American, and Hispanic or Latino patients had consistently higher AAMR than White patients between 1999 and 2022, however. Individuals older than 65 experienced significantly higher AAMR than younger individuals. South and West regions had higher AAMR than Northeast and Midwest regions, with the West and South experiencing the smallest and largest declines in mortality that were statistically significant, respectively (AAPC, -3.04%, -4.66%). TB-related mortality was higher in urban areas, with 20,680 deaths compared to 3,707 deaths in rural areas.</p><p><strong>Conclusion: </strong>Although TB-related mortality has declined in the US overall, this improvement has not been experienced equally by all demographic groups.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"450"},"PeriodicalIF":2.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}